- Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
Kazumasa Yamamoto et al, 2024, Expert Opinion on Drug Safety CrossRef - Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
Ye Tao et al, 2023, Frontiers in Oncology CrossRef - Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi et al, 2024, JCO Precision Oncology CrossRef - Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
Zhengfeng Zhang et al, 2023, Therapeutic Advances in Medical Oncology CrossRef